Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

Melissa Cambron,Jop P. Mostert,Marie B. D'hooghe,Guy Nagels,Barbara Willekens,Jan Debruyne,Luc Algoed,Wim I. M. Verhagen,Raymond Hupperts,Dorothea Heersema,Jacques De Keyser

Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

2019

Melissa Cambron
Jop P. Mostert
Marie B. D'hooghe
Guy Nagels
Barbara Willekens
Jan Debruyne
Luc Algoed
Wim I. M. Verhagen
Raymond Hupperts
Dorothea Heersema
Jacques De Keyser

Background:Preclinical studies suggest that fluoxetine has neuroprotective properties that might reduce axonal degeneration in multiple sclerosis (MS).Objective:To determine whether fluoxetine slow...

Keywords:

Physical therapy
Medicine
Fluoxetine
Internal medicine
Progressive multiple sclerosis
Clinical trial
Experimental autoimmune encephalomyelitis
Pathology
double blind
Oncology
Axonal degeneration
Multiple sclerosis
Neuroprotection

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations